newsfilter
← Latest News
Earnings Call Transcripts·

UBS Global Biopharma Conference - BIOAGE LABS INC

  • Explicit Guidance:

    • NLRP3 Program (BGE-102) Phase 2 Data Readout: Committed to reporting Phase 2 data for the obesity/inflammation trial (QUAD-CV) by the end of the current year.
    • NLRP3 Program (BGE-102) Phase 2 Data Readout (DME): Guiding to readout for the Diabetic Macular Edema (DME) proof-of-concept trial in the second half of the next year (H2 2026).
    • APJ Agonist Program: Targeting IND filing for the first APJ agonist program by the end of the current year.
    • Cash Runway: Current cash balance of ~$350 million expected to finance operations through 2029, covering NLRP3 proof-of-concept trials and APJ proof-of-concept studies.
  • Business-Segment Outlook:

    • NLRP3 Asset (BGE-102) Strategy Shift: Pivoting focus from cardiovascular outcomes (ASCVD) to ophthalmology (DME) and a yet-to-be-announced additional indication. ASCVD outcomes trials remain prepared but deprioritized pending de-risking signals from competitors (e.g., Artemis trial results or Ventix/Ventrix programs).
    • Ophthalmology Expansion: Viewing DME as a "beachhead" entry for a broader ophthalmology strategy, with specific interest in exploring Geographic Atrophy (GA) and Uveitic Macular Edema following DME readouts.
    • APJ Agonist Portfolio: Advancing two APJ agonists (oral and parenteral) in parallel for obesity and metabolic indications, aiming to leverage preclinical data suggesting potential to double weight loss and restore body composition when combined with appetite-suppressing mechanisms.
    • Pipeline Indication Addition: Confirming the addition of a new clinical indication for the NLRP3 program, selection based on upstream efficacy signals where IL-1/IL-6 neutralization has shown clinical benefit.
  • Market and Competitive Outlook:

    • NLRP3 Target Validation: Interpreting recent Zeus trial (IL-6 inhibitor) failure as validation for targeting upstream biology (NLRP3/IL-1 beta) rather than downstream IL-6, citing cytokine processing differences at the plaque level.
    • Competitive Landscape Monitoring: Actively watching competitor outcomes (specifically Artemis for ASCVD and potential Ventix/Ventrix moves) as catalysts for potentially re-initiating cardiovascular outcomes trials.
    • DME Market Dynamics: Targeting a significant patient segment resistant to intravitreal injections (approx. 40% in "watch and wait" categories) and a subset of VEGF-refractory patients, positioning oral therapy as a convenience and efficacy-enhancing alternative to standard of care.
    • Differentiation Strategy: Leveraging novel binding site and deep tissue distribution (brain/retina) to achieve 98% trough IL-1 beta suppression, contrasting with historical NLRP3 approaches targeting the ATPase pocket which had suboptimal CNS/retinal penetration.
  • Macro / Industry Outlook:

    • No specific macroeconomic, FX, or regulatory guidance provided beyond the strategic context of the Zeus trial influencing investor appetite for long-term outcomes trials.
  • Strategic Initiatives:

    • Indication Pivot: Executing a strategic focus shift to ophthalmology to capture value in indications where NLRP3 biology is de-risked and practical for a smaller biotech to advance through POC/pivotal trials.
    • Clinical Development Acceleration: Initiating IND filing for APJ agonists by year-end to re-enter the clinic for obesity/metabolic indications, distinct from a prior discontinued Amgen partnership program.
    • Platform Leverage: Utilizing partnerships with Lilly (therapeutic antibodies) and Novartis (target discovery using human aging/exercise data) to identify and validate novel targets linked to longevity and physical function preservation.
    • M&A/Partnership Context: No immediate M&A guidance; focus remains on internal advancement of current assets to proof-of-concept.
  • Risks and Headwinds to Outlook:

    • Trial Failure Risk: Acknowledges that if the Artemis trial (acute MI) or other competitor trials show definitive signals, strategy could revert to ASCVD; conversely, lack of signal in DME or APJ could delay value creation.
    • Market Adoption Risk: Potential hesitation from patients and providers regarding new oral modalities vs. entrenched intravitreal VEGF standards, though viewing this as an addressable pain point.
    • Safety History: Previously encountered idiosyncratic liver safety issues with a prior APJ program; mitigated by using a novel chemotype and targeting lower doses (<100 mg QD) compared to the prior 300 mg BID regimen.
    • Investor Sentiment: Notes reduced investor appetite for 5-year, half-a-billion-dollar outcomes trials for biomarkers that do not show immediate translation to hard outcomes, necessitating a strategic pivot to shorter-duration POC studies.
  • Management Tone on the Future:

    • Confidence: Expresses high confidence in the Phase 1 safety/efficacy data (98% inhibition, placebo-like tolerability) and the biological differentiation of the NLRP3 platform.
    • Cautious Optimism regarding DME: Views DME as a strategic beachhead with clear pathways to subsequent indications (GA), but maintains that ultimate success depends on reading out "line-of-improvement" data in the 2026 trial.
    • Strategic Discipline: Demonstrates discipline in deprioritizing high-cost cardiovascular outcomes trials until the biology is more definitively de-risked by external data, favoring a "wait and see" approach for ASCVD while aggressively pursuing ophthalmology.
  • Miscellaneous:

    • No specific numbers provided for future revenue, margins, capex, or share count.
    • Timeline Clarification: Clarified that the Zeus trial failure is interpreted as a target-selection issue (IL-6 too downstream) rather than a biology issue, reinforcing the decision to target NLRP3/IL-1 beta.
    • Dosing Strategy: Phase 2 DME trial powered for ~1 line of improvement in BCVA, comparing monotherapy vs. combination with VEGF over a 3-month window.
Company
BIOAGE LABS INC
Keywords
BIOAGE LABS INC